AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUL 11 - (NewsRx.com & NewsRx.net) --
by Michael Greer, senior medical writer - Researchers in Belgium have developed a technique for efficiently transfecting malignant genetic material into immune cells, possibly enabling the development of a potent antitumor vaccine.
"Designing effective strategies to load human dendritic cells (DCs) with tumor antigens is a challenging approach for DC-based tumor vaccines," according to Viggo F.I. Van Tendeloo and colleagues at the University of Antwerp.
Van Tendeloo and coworkers showed that electroporation of tumor messenger RNA (mRNA) allowed it to be effectively integrated into DCs, which subsequently provoked antigen-specific immune responses.
Using malignant mRNA instead of DNA dramatically improved transfection efficiency and reduced cytotoxicity, they said. Almost 90% of DCs successfully integrated electroporated mRNA, and only 15% of those cells subsequently died. By contrast, electroporated DNA was transfected into only 40% of cells, more than half of which perished, study data showed.
After incorporating DCs with mRNA coding for the melanoma antigen Melan-A, the researchers observed potent, Melan-A-specific, HLA-restricted stimulation of a cytotoxic T lymphocyte clone. The strongest such activation was seen with monocyte-derived DCs (Mo-DCs) that matured after mRNA transfection, they noted.
Most DC types demonstrated high-level transgene expression of tumor antigens after transfection, without phenotypic changes ...
Source: HighBeam Research, Tumor RNA Electroporation May Aid Development.(Brief Article)